ClinicalTrials.gov
ClinicalTrials.gov Menu

High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00062335
Recruitment Status : Terminated (low accrual)
First Posted : June 6, 2003
Last Update Posted : September 24, 2012
Sponsor:
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

June 5, 2003
June 6, 2003
September 24, 2012
April 2003
February 2006   (Final data collection date for primary outcome measure)
Maximum tolerated dose as measured by NCI-CTC v2.0 during treatment and up to 6 months after completion of radiotherapy
Not Provided
Complete list of historical versions of study NCT00062335 on ClinicalTrials.gov Archive Site
  • Late toxicity measured every 2 months in year 1, then every 3 months in year 2, and then every 6 months thereafter
  • Disease progression measured every 2 months in year 1, then every 3 months in year 2, and then every 6 months thereafter
Not Provided
Not Provided
Not Provided
 
High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
A Phase I Study On The Feasibility Of High Dose Three Dimensional Conformal Radiotherapy In Patients With Inoperable And Locally Advanced Non Small Cell Lung Cancer

RATIONALE: Using computer systems that create a 3-dimensional picture of the tumor to plan treatment may enable doctors to provide more effective radiation therapy that will cause less damage to normal tissue.

PURPOSE: This phase I trial is studying the side effects and best dose of high-dose 3-dimensional conformal radiation therapy in treating patients with inoperable stage I, stage II, or stage IIIA non-small cell lung cancer.

OBJECTIVES:

  • Determine the optimal dose of high-dose 3-dimensional conformal radiotherapy in patients with inoperable stage I, II, or IIIA non-small cell lung cancer who are treated according to the total lung volume irradiated.
  • Determine the feasibility of this regimen, in terms of local control rates and incidence of distant metastases, in these patients.

OUTLINE: This is an open-label, nonrandomized, dose-escalation, multicenter study. Patients are assigned to 1 of 3 strata according to the total lung volume irradiated (less than 25% vs 25-37% vs over 37%).

  • Stratum I: Patients undergo high-dose 3-dimensional (3-D) conformal radiotherapy 5 days a week for 6 weeks.
  • Stratum II: Patients undergo high-dose 3-D conformal radiotherapy 5 days a week for 5.5-7 weeks.
  • Stratum III: Patients undergo high-dose 3-D conformal radiotherapy 5 days a week for 5.5-6.5 weeks.

Cohorts of 6-15 patients in each stratum receive escalating dose intensities of high-dose 3-D conformal radiotherapy (either by increasing the total dose or by shortening treatment time) until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6, 2 of 15, or 3 of 30 patients experience dose-limiting toxicity.

Patients are followed at 1 month, at least every 2 months for 1 year, every 3 months for 1 year, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 54-135 patients (18-45 per stratum) will be accrued for this study.

Interventional
Phase 1
Masking: None (Open Label)
Primary Purpose: Treatment
Lung Cancer
Radiation: radiation therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
14
Not Provided
Not Provided
February 2006   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed non-small cell lung cancer

    • Medically inoperable stage I or II disease
    • Stage III disease eligible provided the following are true:

      • No supraclavicular node involvement
      • No peripherally located lower lobe tumor AND contralateral upper mediastinal node involvement
  • No distant metastasis
  • No malignant pleural or pericardial effusion

PATIENT CHARACTERISTICS:

Age

  • Not specified

Performance status

  • WHO 0-2

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Cardiovascular

  • No prior myocardial infarction
  • No prior complete bundle branch block
  • No other prior cardiovascular disease resulting in New York Heart Association class III or IV heart disease
  • No clinically significant cardiac arrhythmias
  • No congestive heart failure

Pulmonary

  • FEV_1 at least 1.2 L OR
  • DLCO at least 60%

Other

  • No other prior or concurrent malignancy except cured basal cell skin cancer or carcinoma in situ of the cervix
  • No intractable or uncontrolled infection
  • No psychological, familial, social, or geographical condition that would preclude study compliance and follow-up
  • Able to tolerate a course of radiotherapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • At least 3 weeks since prior chemotherapy
  • No prior anthracyclines
  • No concurrent chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • No prior radiotherapy to the chest area

Surgery

  • No prior therapeutic surgery to the chest area

Other

  • No other prior therapy to the chest area
Sexes Eligible for Study: All
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   France,   Switzerland
 
 
NCT00062335
EORTC-22994
EORTC-22994
Not Provided
Not Provided
Not Provided
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Not Provided
Study Chair: Jacques Bernier, MD, PhD Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni
European Organisation for Research and Treatment of Cancer - EORTC
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP